IKT vs NRXP

Analysts rate Inhibikase Therapeutics, Inc.

(IKT) a "Hold" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Inhibikase Therapeutics, Inc.

(IKT) delivered a total return of -95. 3%, compared to -97. 9% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: NRXP returned -95. 9% versus IKT's -97. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Inhibikase Therapeutics, Inc.

(IKT) is the lower-risk stock at 1. 98β versus NRx Pharmaceuticals, Inc. 's 2. 08β — meaning NRXP is approximately 5% more volatile than IKT relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Inhibikase Therapeutics, Inc.

grew EPS 57. 8% year-over-year, compared to 43. 9% for NRx Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Inhibikase Therapeutics, Inc.

(IKT) is the more profitable company, earning 0. 0% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IKT leads at 0. 0% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — NRXP leads at 58. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Inhibikase Therapeutics, Inc.

(IKT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IKT: -97. 2%, NRXP: -95. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.